Guiding Optimal Compound Design and Development: A One-day Symposium

19th March 2015 | Cambridge, MA, USA

Cambridge, UK – 20th January 2015 – Cresset, Optibrium, Lhasa Limited and COSMOlogic, providers of chemistry software and services, are partnering to present ‘Guiding Optimal Compound Design and Development: A One-day Symposium’ on 19th March 2015 at the British Consulate General in Cambridge, MA, USA.

“Chaired by Dr Paul Leeson, formerly Consultant to GlaxoSmithKline and Head of Medicinal Chemistry at AstraZeneca, the scientific symposium will present and discuss technologies that lead to successful compound discovery and development,” says Dr Robert Scoffin, Cresset’s CEO. “There will be presentations on software for intuitive molecular design, 3D-QSAR interpretation and knowledge based toxicity prediction. Software demonstrations will be given by Cresset, Optibrium, Lhasa Limited and COSMOlogic.”

Computational, medicinal and synthetic chemists as well as researchers working in the pharmaceutical, biotechnology, flavor, fragrance and agrochemical industries will benefit from attendance. The following companies will present at the symposium:

  • Paul Leeson Consulting Ltd
  • Novartis
  • Lilly Open Innovation Drug Discovery
  • Pfizer
  • Massachusetts College of Pharmacy and Health Sciences
  • Broad Institute
  • Cresset
  • Optibrium
  • Lhasa Limited
  • COSMOlogic

Find out more and register free.